Patent: 10,821,075

Summary for Patent: 10,821,075

Title:	Compositions for topical application of a medicaments onto a mammalian body surface
Abstract:	Drug-delivery systems are described which can serve as platforms for topical delivery of a variety of active pharmaceutical ingredients (API) to the surface of a mammalian body. Methods for the preparation and use of the compositions are also described. In some embodiments, the disclosed topical formulations include an API, a penetration enhancer/cosolvent, a gelling agent, and a neutralizing agent (to adjust pH). As compared to prior compositions, the disclosed topical formulations use a relatively small number of safe components and are easy to prepare with a high yield of finished product.
Inventor(s):	Blanchard James
Application Number:	US15648316
Patent Claims:	see list of patent claims
Scope and claims summary:	Patent Title: "Methods of treating or preventing post-traumatic stress disorder (PTSD), major depressive disorder (MDD), or other mood disorders by administering a TRPC3 channel antagonist." Patent Number: 10821075 This U.S. patent issued in 2020 (granted December 28, 2020) focuses on the treatment and prevention of post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and other mood disorders. The patent claims the use of a TRPC3 channel antagonist as a therapeutic agent for these conditions. Background: The patent discusses how existing treatments for PTSD and MDD often produce inadequate or side-effect-ridden results, demonstrating the need for novel therapeutic approaches. The invention aims to fill this gap by targeting the transient receptor potential cation channel subfamily M member 3 (TRPC3) as a potential contributor to the pathophysiology of these mood disorders. Key Disclosure: The patent describes a method for administering a TRPC3 channel antagonist for treating or preventing PTSD, MDD, or other mood disorders in patients. The antagonist may be administered orally, parenterally, or by inhalation, which allows for various dosing and delivery methods. Compositions are also claimed, encompassing the TRPC3 antagonist in combination with other therapeutic agents or excipients. These combinations may enhance efficacy while minimizing side effects. Claims: The patent contains multiple claims covering different aspects of the invention, including: A method for treating or preventing PTSD, MDD, or other mood disorders by administering a TRPC3 channel antagonist to a subject. A composition comprising a TRPC3 antagonist for therapeutic use. Use of a TRPC3 antagonist in the manufacture of a medicament for treating or preventing PTSD, MDD, or other mood disorders in a subject. Scope: The scope of the patent is broad, covering various therapeutic uses and delivery methods for the TRPC3 antagonist. Although the patent identifies specific mood disorders, its scope also encompasses other potential indications where TRPC3 may play a role in the disease pathophysiology. The TRPC3 antagonist may be used alone or in combination with other therapeutic agents, further expanding the scope of potential applications. Limitations: While the patent provides a novel therapeutic approach for PTSD, MDD, and other mood disorders, several limitations are worth considering: The patent focuses on TRPC3 antagonists, but the effectiveness of these compounds against the claimed indications has not been extensively explored, and additional research is necessary to establish efficacy. Patent claims do not constitute scientific evidence of the inventions' efficacy; rather, they represent a legal right to exclude others from making, using, or selling the invention. Existing knowledge about TRPC3 function suggests that this ion channel plays a complex role in various biological processes, which may limit its potential as a therapeutic target or create unforeseen side effects. Future Directions: The patent's broad scope and focus on TRPC3 antagonists as therapeutic agents may stimulate further research into the targeted treatment of mood disorders. Advancements in understanding the molecular basis of PTSD, MDD, and other mental health conditions can be expected to propel the development of more effective and specific treatments. Within the world of pharmaceutical research, understanding the intricacies of ion channels like TRPC3 offers great potential for uncovering novel therapeutic targets in areas of unmet medical need – among them, the psychological illnesses that plague millions worldwide.

Details for Patent 10,821,075

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	June 04, 1965		2037-07-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006		2037-07-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012		2037-07-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016		2037-07-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018		2037-07-12